Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...

Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

In efforts to reduce child mortality, the Tafo Government Hospital is attempting to retool the Pediatrics Unit.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of ...

HDFN has affected 2 of Andrea Renzi's 5 children and turned her into an activist on behalf of other mothers and families touched by the disease.

Photoimmunotherapy with the M@P nanoplatform offers a novel approach, triggering cancer cell death and boosting immune ...

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

The Tafo government hospital in the Ashanti Region has received four essential life-saving equipment from the Kofi Job ...

The Department of Health (DOH) has recently provided new medical equipment to Romblon Provincial Hospital (RPH) to enhance ...